Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic target of rapamycin (mTOR) inhibitor everolimus and ALK inhibitor crizotinib have...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res Treat
Main Authors: Xu, Wendan, Kim, Ji-Won, Jung, Woo June, Koh, Youngil, Yoon, Sung-Soo
Format: Artigo
Jezik:Inglês
Izdano: Korean Cancer Association 2018
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912135/
https://ncbi.nlm.nih.gov/pubmed/28675026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2016.357
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki